Shattuck ended the third quarter of 2023 with approximately $101.1 million in cash and cash equivalents and investments. The company expects its cash and cash equivalents and investments as of September 30, 2023, together with the proceeds from the $50 million registered offering of common stock and concurrent private placement of pre-funded warrants in December of 2023, to be sufficient to fund operations into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STTK:
- Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
- Largest borrow rate increases among liquid names
- Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- Shattuck Labs prices 4.65M shares at $6.45 in registered offering
- Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients